Efficacy and safety of sublingual immunotherapy using house dust mite tablet for 1–4 years old children with perennial allergic rhinitis
Background Sublingual immunotherapy (SLIT) for perennial allergic rhinitis (AR) has not been extensively studied in preschoolers. We investigated the efficacy and safety of house dust mite (HDM) SLIT‐tablet for children aged 1–4 years. Methods Children aged 1–4 years with AR were divided into SLIT (...
Gespeichert in:
| Veröffentlicht in: | Pediatric allergy and immunology 2024-07, Vol.35 (7), p.e14203-n/a |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 7 |
| container_start_page | e14203 |
| container_title | Pediatric allergy and immunology |
| container_volume | 35 |
| creator | Sasamoto, Koki Nagakura, Ken‐ichi Asaumi, Tomoyuki Fusayasu, Naoko Ohashi‐Doi, Katsuyo Yanagida, Noriyuki Sato, Sakura Ebisawa, Motohiro |
| description | Background
Sublingual immunotherapy (SLIT) for perennial allergic rhinitis (AR) has not been extensively studied in preschoolers. We investigated the efficacy and safety of house dust mite (HDM) SLIT‐tablet for children aged 1–4 years.
Methods
Children aged 1–4 years with AR were divided into SLIT (n = 22) and control (n = 12) groups based on their guardians' preferences. The SLIT group received a daily dose of 10,000 JAU of HDM SLIT‐tablet for 12 months, whereas the control group received symptomatic treatment only.
Results
The baseline median age was 41 and 34 months in the SLIT and control groups, respectively, and the median AR symptom score was 4 for both groups. Compared with baseline, the AR symptom score had decreased significantly in the SLIT group after 12 months (score: 3, p = .002), whereas it tended to increase in the control group (score: 6, p = .08). Adverse reactions to SLIT were mild and occurred in eight patients (36%). In the SLIT group, Dermatophagoides (D.) farinae‐specific IgE (sIgE) levels increased during the first 6 months and decreased to baseline levels at 12 months. In the control group, D. farinae‐sIgE levels had increased significantly at 12 months compared to baseline (p = .01). D. farinae‐specific IgG4 and HDM IgE‐blocking factor levels were significantly increased at 12 months compared to baseline in the SLIT group only (p |
| doi_str_mv | 10.1111/pai.14203 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3084032017</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3084032017</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2153-be083bd5061ab91baf6109b73bb9992837e7dfac42ebab788e03fa24e5e548b3</originalsourceid><addsrcrecordid>eNp1kLtOHTEQQK2IKNzcpOAH0JSkWLDX-3KJECRISFDQr8a7Y9aR94HtFdqOFomOP-RLsuQSurgZa3R0pDmMHQh-LNZ3MqE9FlnK5Se2EVKpRHJZ7bENVzxPCpGX--xrCL85F6UsxBe2LxXP8kLlG_Z8boxtsFkAhxYCGooLjAbCrJ0d7mZ0YPt-HsbYkcdpgTmsa-jGORC0c4jQ20gQUTuKYEYP4vXxJXt9fFoIfYDRtdB01rWeBniwsYOJ1u9gVzE6R_7ONuA7O9howzf22aAL9P19btntxfnt2a_k6vrn5dnpVdKkIpeJJl5J3ea8EKiV0GgKwZUupdZKqbSSJZWtwSZLSaMuq4q4NJhmlFOeVVpu2dFOO_nxfqYQ696GhpzDgda7asmrjMv0rdaW_dihjR9D8GTqydse_VILXr-1r9f29d_2K3v4rp11T-0H-S_2CpzsgAfraPm_qb45vdwp_wCfcpKN</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3084032017</pqid></control><display><type>article</type><title>Efficacy and safety of sublingual immunotherapy using house dust mite tablet for 1–4 years old children with perennial allergic rhinitis</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Sasamoto, Koki ; Nagakura, Ken‐ichi ; Asaumi, Tomoyuki ; Fusayasu, Naoko ; Ohashi‐Doi, Katsuyo ; Yanagida, Noriyuki ; Sato, Sakura ; Ebisawa, Motohiro</creator><creatorcontrib>Sasamoto, Koki ; Nagakura, Ken‐ichi ; Asaumi, Tomoyuki ; Fusayasu, Naoko ; Ohashi‐Doi, Katsuyo ; Yanagida, Noriyuki ; Sato, Sakura ; Ebisawa, Motohiro</creatorcontrib><description>Background
Sublingual immunotherapy (SLIT) for perennial allergic rhinitis (AR) has not been extensively studied in preschoolers. We investigated the efficacy and safety of house dust mite (HDM) SLIT‐tablet for children aged 1–4 years.
Methods
Children aged 1–4 years with AR were divided into SLIT (n = 22) and control (n = 12) groups based on their guardians' preferences. The SLIT group received a daily dose of 10,000 JAU of HDM SLIT‐tablet for 12 months, whereas the control group received symptomatic treatment only.
Results
The baseline median age was 41 and 34 months in the SLIT and control groups, respectively, and the median AR symptom score was 4 for both groups. Compared with baseline, the AR symptom score had decreased significantly in the SLIT group after 12 months (score: 3, p = .002), whereas it tended to increase in the control group (score: 6, p = .08). Adverse reactions to SLIT were mild and occurred in eight patients (36%). In the SLIT group, Dermatophagoides (D.) farinae‐specific IgE (sIgE) levels increased during the first 6 months and decreased to baseline levels at 12 months. In the control group, D. farinae‐sIgE levels had increased significantly at 12 months compared to baseline (p = .01). D. farinae‐specific IgG4 and HDM IgE‐blocking factor levels were significantly increased at 12 months compared to baseline in the SLIT group only (p < .001). A lower wheezing frequency was seen in the SLIT group (0.3%) compared to the control group (0.7%).
Conclusion
This pilot study demonstrated the efficacy, safety, and immunomodulatory effects of HDM SLIT‐tablet in preschoolers with AR.</description><identifier>ISSN: 0905-6157</identifier><identifier>ISSN: 1399-3038</identifier><identifier>EISSN: 1399-3038</identifier><identifier>DOI: 10.1111/pai.14203</identifier><identifier>PMID: 39045695</identifier><language>eng</language><publisher>England</publisher><subject>allergen immunotherapy ; Animals ; Antigens, Dermatophagoides - administration & dosage ; Antigens, Dermatophagoides - immunology ; Child, Preschool ; Female ; house dust mite ; Humans ; IgE‐blocking factor ; Immunoglobulin E - blood ; Infant ; Male ; preschool children ; Pyroglyphidae - immunology ; Rhinitis, Allergic, Perennial - immunology ; Rhinitis, Allergic, Perennial - therapy ; sublingual immunotherapy ; Sublingual Immunotherapy - adverse effects ; Sublingual Immunotherapy - methods ; Tablets ; Treatment Outcome</subject><ispartof>Pediatric allergy and immunology, 2024-07, Vol.35 (7), p.e14203-n/a</ispartof><rights>2024 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2153-be083bd5061ab91baf6109b73bb9992837e7dfac42ebab788e03fa24e5e548b3</cites><orcidid>0000-0002-9055-6453 ; 0000-0002-5104-6952 ; 0000-0002-9649-8135 ; 0000-0001-9643-744X ; 0000-0002-7464-5421 ; 0000-0002-9381-9044 ; 0000-0003-4117-558X ; 0000-0003-3674-0759</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fpai.14203$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fpai.14203$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39045695$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sasamoto, Koki</creatorcontrib><creatorcontrib>Nagakura, Ken‐ichi</creatorcontrib><creatorcontrib>Asaumi, Tomoyuki</creatorcontrib><creatorcontrib>Fusayasu, Naoko</creatorcontrib><creatorcontrib>Ohashi‐Doi, Katsuyo</creatorcontrib><creatorcontrib>Yanagida, Noriyuki</creatorcontrib><creatorcontrib>Sato, Sakura</creatorcontrib><creatorcontrib>Ebisawa, Motohiro</creatorcontrib><title>Efficacy and safety of sublingual immunotherapy using house dust mite tablet for 1–4 years old children with perennial allergic rhinitis</title><title>Pediatric allergy and immunology</title><addtitle>Pediatr Allergy Immunol</addtitle><description>Background
Sublingual immunotherapy (SLIT) for perennial allergic rhinitis (AR) has not been extensively studied in preschoolers. We investigated the efficacy and safety of house dust mite (HDM) SLIT‐tablet for children aged 1–4 years.
Methods
Children aged 1–4 years with AR were divided into SLIT (n = 22) and control (n = 12) groups based on their guardians' preferences. The SLIT group received a daily dose of 10,000 JAU of HDM SLIT‐tablet for 12 months, whereas the control group received symptomatic treatment only.
Results
The baseline median age was 41 and 34 months in the SLIT and control groups, respectively, and the median AR symptom score was 4 for both groups. Compared with baseline, the AR symptom score had decreased significantly in the SLIT group after 12 months (score: 3, p = .002), whereas it tended to increase in the control group (score: 6, p = .08). Adverse reactions to SLIT were mild and occurred in eight patients (36%). In the SLIT group, Dermatophagoides (D.) farinae‐specific IgE (sIgE) levels increased during the first 6 months and decreased to baseline levels at 12 months. In the control group, D. farinae‐sIgE levels had increased significantly at 12 months compared to baseline (p = .01). D. farinae‐specific IgG4 and HDM IgE‐blocking factor levels were significantly increased at 12 months compared to baseline in the SLIT group only (p < .001). A lower wheezing frequency was seen in the SLIT group (0.3%) compared to the control group (0.7%).
Conclusion
This pilot study demonstrated the efficacy, safety, and immunomodulatory effects of HDM SLIT‐tablet in preschoolers with AR.</description><subject>allergen immunotherapy</subject><subject>Animals</subject><subject>Antigens, Dermatophagoides - administration & dosage</subject><subject>Antigens, Dermatophagoides - immunology</subject><subject>Child, Preschool</subject><subject>Female</subject><subject>house dust mite</subject><subject>Humans</subject><subject>IgE‐blocking factor</subject><subject>Immunoglobulin E - blood</subject><subject>Infant</subject><subject>Male</subject><subject>preschool children</subject><subject>Pyroglyphidae - immunology</subject><subject>Rhinitis, Allergic, Perennial - immunology</subject><subject>Rhinitis, Allergic, Perennial - therapy</subject><subject>sublingual immunotherapy</subject><subject>Sublingual Immunotherapy - adverse effects</subject><subject>Sublingual Immunotherapy - methods</subject><subject>Tablets</subject><subject>Treatment Outcome</subject><issn>0905-6157</issn><issn>1399-3038</issn><issn>1399-3038</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kLtOHTEQQK2IKNzcpOAH0JSkWLDX-3KJECRISFDQr8a7Y9aR94HtFdqOFomOP-RLsuQSurgZa3R0pDmMHQh-LNZ3MqE9FlnK5Se2EVKpRHJZ7bENVzxPCpGX--xrCL85F6UsxBe2LxXP8kLlG_Z8boxtsFkAhxYCGooLjAbCrJ0d7mZ0YPt-HsbYkcdpgTmsa-jGORC0c4jQ20gQUTuKYEYP4vXxJXt9fFoIfYDRtdB01rWeBniwsYOJ1u9gVzE6R_7ONuA7O9howzf22aAL9P19btntxfnt2a_k6vrn5dnpVdKkIpeJJl5J3ea8EKiV0GgKwZUupdZKqbSSJZWtwSZLSaMuq4q4NJhmlFOeVVpu2dFOO_nxfqYQ696GhpzDgda7asmrjMv0rdaW_dihjR9D8GTqydse_VILXr-1r9f29d_2K3v4rp11T-0H-S_2CpzsgAfraPm_qb45vdwp_wCfcpKN</recordid><startdate>202407</startdate><enddate>202407</enddate><creator>Sasamoto, Koki</creator><creator>Nagakura, Ken‐ichi</creator><creator>Asaumi, Tomoyuki</creator><creator>Fusayasu, Naoko</creator><creator>Ohashi‐Doi, Katsuyo</creator><creator>Yanagida, Noriyuki</creator><creator>Sato, Sakura</creator><creator>Ebisawa, Motohiro</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-9055-6453</orcidid><orcidid>https://orcid.org/0000-0002-5104-6952</orcidid><orcidid>https://orcid.org/0000-0002-9649-8135</orcidid><orcidid>https://orcid.org/0000-0001-9643-744X</orcidid><orcidid>https://orcid.org/0000-0002-7464-5421</orcidid><orcidid>https://orcid.org/0000-0002-9381-9044</orcidid><orcidid>https://orcid.org/0000-0003-4117-558X</orcidid><orcidid>https://orcid.org/0000-0003-3674-0759</orcidid></search><sort><creationdate>202407</creationdate><title>Efficacy and safety of sublingual immunotherapy using house dust mite tablet for 1–4 years old children with perennial allergic rhinitis</title><author>Sasamoto, Koki ; Nagakura, Ken‐ichi ; Asaumi, Tomoyuki ; Fusayasu, Naoko ; Ohashi‐Doi, Katsuyo ; Yanagida, Noriyuki ; Sato, Sakura ; Ebisawa, Motohiro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2153-be083bd5061ab91baf6109b73bb9992837e7dfac42ebab788e03fa24e5e548b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>allergen immunotherapy</topic><topic>Animals</topic><topic>Antigens, Dermatophagoides - administration & dosage</topic><topic>Antigens, Dermatophagoides - immunology</topic><topic>Child, Preschool</topic><topic>Female</topic><topic>house dust mite</topic><topic>Humans</topic><topic>IgE‐blocking factor</topic><topic>Immunoglobulin E - blood</topic><topic>Infant</topic><topic>Male</topic><topic>preschool children</topic><topic>Pyroglyphidae - immunology</topic><topic>Rhinitis, Allergic, Perennial - immunology</topic><topic>Rhinitis, Allergic, Perennial - therapy</topic><topic>sublingual immunotherapy</topic><topic>Sublingual Immunotherapy - adverse effects</topic><topic>Sublingual Immunotherapy - methods</topic><topic>Tablets</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sasamoto, Koki</creatorcontrib><creatorcontrib>Nagakura, Ken‐ichi</creatorcontrib><creatorcontrib>Asaumi, Tomoyuki</creatorcontrib><creatorcontrib>Fusayasu, Naoko</creatorcontrib><creatorcontrib>Ohashi‐Doi, Katsuyo</creatorcontrib><creatorcontrib>Yanagida, Noriyuki</creatorcontrib><creatorcontrib>Sato, Sakura</creatorcontrib><creatorcontrib>Ebisawa, Motohiro</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Pediatric allergy and immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sasamoto, Koki</au><au>Nagakura, Ken‐ichi</au><au>Asaumi, Tomoyuki</au><au>Fusayasu, Naoko</au><au>Ohashi‐Doi, Katsuyo</au><au>Yanagida, Noriyuki</au><au>Sato, Sakura</au><au>Ebisawa, Motohiro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and safety of sublingual immunotherapy using house dust mite tablet for 1–4 years old children with perennial allergic rhinitis</atitle><jtitle>Pediatric allergy and immunology</jtitle><addtitle>Pediatr Allergy Immunol</addtitle><date>2024-07</date><risdate>2024</risdate><volume>35</volume><issue>7</issue><spage>e14203</spage><epage>n/a</epage><pages>e14203-n/a</pages><issn>0905-6157</issn><issn>1399-3038</issn><eissn>1399-3038</eissn><abstract>Background
Sublingual immunotherapy (SLIT) for perennial allergic rhinitis (AR) has not been extensively studied in preschoolers. We investigated the efficacy and safety of house dust mite (HDM) SLIT‐tablet for children aged 1–4 years.
Methods
Children aged 1–4 years with AR were divided into SLIT (n = 22) and control (n = 12) groups based on their guardians' preferences. The SLIT group received a daily dose of 10,000 JAU of HDM SLIT‐tablet for 12 months, whereas the control group received symptomatic treatment only.
Results
The baseline median age was 41 and 34 months in the SLIT and control groups, respectively, and the median AR symptom score was 4 for both groups. Compared with baseline, the AR symptom score had decreased significantly in the SLIT group after 12 months (score: 3, p = .002), whereas it tended to increase in the control group (score: 6, p = .08). Adverse reactions to SLIT were mild and occurred in eight patients (36%). In the SLIT group, Dermatophagoides (D.) farinae‐specific IgE (sIgE) levels increased during the first 6 months and decreased to baseline levels at 12 months. In the control group, D. farinae‐sIgE levels had increased significantly at 12 months compared to baseline (p = .01). D. farinae‐specific IgG4 and HDM IgE‐blocking factor levels were significantly increased at 12 months compared to baseline in the SLIT group only (p < .001). A lower wheezing frequency was seen in the SLIT group (0.3%) compared to the control group (0.7%).
Conclusion
This pilot study demonstrated the efficacy, safety, and immunomodulatory effects of HDM SLIT‐tablet in preschoolers with AR.</abstract><cop>England</cop><pmid>39045695</pmid><doi>10.1111/pai.14203</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-9055-6453</orcidid><orcidid>https://orcid.org/0000-0002-5104-6952</orcidid><orcidid>https://orcid.org/0000-0002-9649-8135</orcidid><orcidid>https://orcid.org/0000-0001-9643-744X</orcidid><orcidid>https://orcid.org/0000-0002-7464-5421</orcidid><orcidid>https://orcid.org/0000-0002-9381-9044</orcidid><orcidid>https://orcid.org/0000-0003-4117-558X</orcidid><orcidid>https://orcid.org/0000-0003-3674-0759</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0905-6157 |
| ispartof | Pediatric allergy and immunology, 2024-07, Vol.35 (7), p.e14203-n/a |
| issn | 0905-6157 1399-3038 1399-3038 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3084032017 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | allergen immunotherapy Animals Antigens, Dermatophagoides - administration & dosage Antigens, Dermatophagoides - immunology Child, Preschool Female house dust mite Humans IgE‐blocking factor Immunoglobulin E - blood Infant Male preschool children Pyroglyphidae - immunology Rhinitis, Allergic, Perennial - immunology Rhinitis, Allergic, Perennial - therapy sublingual immunotherapy Sublingual Immunotherapy - adverse effects Sublingual Immunotherapy - methods Tablets Treatment Outcome |
| title | Efficacy and safety of sublingual immunotherapy using house dust mite tablet for 1–4 years old children with perennial allergic rhinitis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T23%3A51%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20safety%20of%20sublingual%20immunotherapy%20using%20house%20dust%20mite%20tablet%20for%201%E2%80%934%E2%80%89years%20old%20children%20with%20perennial%20allergic%20rhinitis&rft.jtitle=Pediatric%20allergy%20and%20immunology&rft.au=Sasamoto,%20Koki&rft.date=2024-07&rft.volume=35&rft.issue=7&rft.spage=e14203&rft.epage=n/a&rft.pages=e14203-n/a&rft.issn=0905-6157&rft.eissn=1399-3038&rft_id=info:doi/10.1111/pai.14203&rft_dat=%3Cproquest_cross%3E3084032017%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3084032017&rft_id=info:pmid/39045695&rfr_iscdi=true |